NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1167.20 -8.30 (-0.71%)

1.4M NSE+BSE Volume

NSE 19 Jan, 2026 3:31 PM (IST)

97,418.1

Market Cap

High in industry

Beta 1Year

Low volatility

Board Meeting

The next board meeting for Dr. Reddy's Labs is on 21 Jan 2026 for the purpose of Quarterly Results See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

12 Dec 2025

1167.20

-0.71%

Growth levers in place, but near-term earnings drag limits upside

Neutral: Dr. Reddy's Laboratories Ltd.

Motilal Oswal

While increased competition in g-Revlmid would weigh on DRRD’s near-term performance, the company is implementing efforts to improve growth prospects over the next 2-3 years.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

29 Oct 2025

1167.20

-0.71%

A muted quarter as robust growth across non-US markets was offset by US pricing pressure.

Sell: Dr. Reddy's Laboratories Ltd.

Target

Deven Choksey

Although the company continues to strengthen its presence through new launches, portfolio expansion, and biosimilar development, persistent pricing pressure in the U.S. generics business and adverse product mix are expected to remain key headwinds to its overall profitability.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1167.20

-0.71%

Result Update:Dr Reddys Labs

Hold: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We maintain our HOLD recommendation on the stock.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1167.20

-0.71%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Target

ICICI Direct

About the stock: Dr Reddy's (DRL) business encompasses generic formulations sales across US, Europe, RoW markets and branded generics in India and Russia CIS. The business also comprises of API sales under the head PSAI. The company...

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1167.20

-0.71%

GM weakness persists; pipeline uncertainty heightens

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

The 2QFY26 margin performance of Dr Reddy’s was marginally weaker than our expectations (in line with street estimates; adjusted for one-offs), with the gross margin (GM) decline being sharper than our expectations (at 55%, GM logged at its lowest since the launch of gRevlimid) and largely a consequence of lower-than-expected gRevlimid sales.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1167.20

-0.71%

Launches critical to revive growth

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

Dr. Reddy’s Laboratories’ (DRL) Q2FY26 revenue was slightly ahead of our expectations, though EBITDA and profit were in line. Revenue growth of 9.8% YoY was boosted by consolidation (65-70%) of the acquired NRT portfolio (~8% of sales) and acquisition of other branded products.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1167.20

-0.71%

Dr. Reddy's Laboratories (DRRD IN) Q2FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Prabhudas Lilladhar

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

25 Oct 2025

1167.20

-0.71%

Earnings steady despite US pressure

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr Reddy’s Labs (DRRD) delivered slightly better-than-expected revenue/EBITDA (3%/5% beat) in 2QFY26. Higher other income and a lower tax rate led to a 14% beat in PAT.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

11 Sep 2025

1167.20

-0.71%

Stock Flash

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Dr. Reddy’s Laboratories Ltd. has entered into a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the STUGERON® brand along with its leading local brands STUGERON® FORTE and STUGERON® PLUS.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

29 Jul 2025

1167.20

-0.71%

Price Erosion across the US portfolio to remain the key overhang for its overall business

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Revenue: For Q1FY26, the revenue increased by 11.4% YoY (+0.5% QoQ) to INR 85,721 Mn, below our estimates by 3.0%, led by weakness in North America, which was partially offset by higher momentum across Europe and the Emerging markets.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Is Dr. Reddy's Laboratories Ltd. worth buying?

539 Votes:

Buy 77.92%

Sell 12.62%

Hold 9.46%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf